Efgartigimod PH20 SC

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis18
14Chronic inflammatory demyelinating polyneuropathy31
35Pemphigus16
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura22
162Pemphigoid23

11. Myasthenia gravis


Clinical trials : 439Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 223Drugs : 119 - (DrugBank : 28) / Drug target genes : 11 - Drug target pathways : 22 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

35. Pemphigus


Clinical trials : 120Drugs : 109 - (DrugBank : 40) / Drug target genes : 28 - Drug target pathways : 167 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 575Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

162. Pemphigoid


Clinical trials : 128Drugs : 108 - (DrugBank : 49) / Drug target genes : 35 - Drug target pathways : 143 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries